Press Releases TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
0.7301 ^USD	+18.48%		-37.06%	-88.92%

04-22	Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI
04-22	Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TransCode Therapeutics Open Letter to Shareholders	05-13	AQ
TransCode Therapeutics : Shareholder Meeting - Form 8-K	04-23	PU
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors	04-15	AQ
TransCode Therapeutics Reports 2023 Results; Provides Business Update	04-03	AQ
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	03-28	AQ
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment	03-11	AQ
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic	02-20	AQ
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market	01-31	AQ
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer	01-29	AQ
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering	01-22	AQ
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering	01-18	AQ
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO	01-12	AQ
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split	01-11	AQ
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives	01-04	AQ
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138	12-12	AQ
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium	12-05	AQ
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules	12-04	AQ
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules	11-30	AQ
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update	11-14	AQ
TransCode Therapeutics Withdraws Public Offering	23-10-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Press Releases

Filters